



ASX release

29 June 2016

\$0.6 million pharmaceutical trial extension
Total contract increases to \$1.4 million

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central aortic blood pressures and arterial stiffness noninvasively, today announced that it has signed an extension to a contract with a major international pharmaceutical company. AtCor is supplying SphygmoCor systems and clinical trial support services for a study being conducted in North America, Europe and Asia, which is expected to conclude in 2018. The extension increases the value of the pharmaceutical services contract by \$0.6 million to \$1.4 million (US\$1.0 million).

Duncan Ross, CEO of AtCor Medical said: “Our global pharmaceutical customers place great value in understanding the central pressures effects of new drugs. Over time AtCor has broadened the range of disease states where SphygmoCor is used beyond hypertension. Other diseases that have been studied include chronic obstructive pulmonary disease, kidney disease, heart failure, gout and psoriasis and diabetes, which is the subject of this trial.”

Diabetes is a major health issue around the world. In 2014 an estimated 21.9 million people were diagnosed with the disease in the USA, including 1.4 million new cases identified in that year¹.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central aortic blood pressure non-invasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Media enquiries to:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au

Peter Manley – AtCor Medical CFO
+61 (2) 8815 8811
p.manley@atcormedical.com

¹ Centers for Disease Control and Prevention

SphygmoCor® is a registered trademark of AtCor Medical Pty Ltd and its related parties